CAT-192 APPEARS TOLERABLE

Article

Cambridge Antibody Technology and Genzyme Corp. announced preliminary results from a Phase I/II clinical trial of CAT-192, a human anti-TGF(Beta)1 monoclonal antibody. The primary objective of the trial was to assess the safety, tolerability, and pharmacokinetics of CAT-192 in patients suffering from diffuse systemic sclerosis.

Related Videos
Related Content

Data-Driven Advice for Health Care Workers Experiencing Contact Dermatitis

September 29th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Rocco Serrao, MD Looks Ahead to Bimekizumab’s Approval

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Dermatology Times: September 2023

September 28th 2023

85% of Survey Respondents Do Not Know What Actinic Keratosis Is

September 28th 2023

Data-Driven Advice for Health Care Workers Experiencing Contact Dermatitis

September 29th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Rocco Serrao, MD Looks Ahead to Bimekizumab’s Approval

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Dermatology Times: September 2023

September 28th 2023

85% of Survey Respondents Do Not Know What Actinic Keratosis Is

September 28th 2023

Data-Driven Advice for Health Care Workers Experiencing Contact Dermatitis

September 29th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Rocco Serrao, MD Looks Ahead to Bimekizumab’s Approval

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Dermatology Times: September 2023

September 28th 2023

85% of Survey Respondents Do Not Know What Actinic Keratosis Is

September 28th 2023
© 2023 MJH Life Sciences

All rights reserved.